Therapeutic Potential of Rivastigmine for Managing Complications Associated with Ischemic Stroke

Abstract

Stroke continues to be the world’s primary cause of morbidity and mortality, frequently with incapacitating consequences like movement dysfunction, cognitive decline, and neurological impairments. It is essential to manage stroke effectively to lessen its negative effects and enhance patient outcomes. The potential neuroprotective benefits of acetylcholinesterase inhibitors may assist maintain the integrity of brain tissue and lessen the damage that neurons may sustain after a stroke, making them a promising option in this situation. This comprehensive thesis explores the neuroprotective benefits of an acetylcholinesterase inhibitor, Rivastigmine, in relation to stroke outcomes in a variety of ways. Using an advanced integrative methodology, this study includes behavioral evaluations, in silico analysis, histopathological results, and molecular studies to give a comprehensive picture of the possible mechanisms behind therapeutic effects of Rivastigmine. Within the field of computer modelling, the docking interactions between SOD2 and TLR4, the target proteins of Rivastigmine, provide detailed structural information that directs further experimental validations. Following Rivastigmine treatment, the behavioral tests conducted exhibited improvements in cognitive, motor, and social domains. These results were further corroborated by histopathological analysis, which shows neuroprotective effects in Rivastigmine treated group as opposed to surgery (MCAO) group. Post Rivastigmine treatment, real-time PCR data showed a rise in SOD2 and a decrease in TLR4 levels in surgery (MCAO) rats, exhibiting antioxidant and anti-inflammatory effects of Rivastigmine. These findings provide interesting directions for future neuroprotective approaches and shed light on the possible therapeutic implications of Rivastigmine in reducing neurodegeneration that occurs in stroke.